Xin Kevin Z, Prescott Christina R
Department of Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, MD, USA.
Clin Ophthalmol. 2019 Aug 9;13:1517-1522. doi: 10.2147/OPTH.S213289. eCollection 2019.
To evaluate the effects of selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) medications in combination with cataract surgery in treating amblyopia in adult patients.
A retrospective chart review study was conducted on patients who had undergone cataract surgery at the Johns Hopkins Hospital Wilmer Eye Institute. Six inclusion criteria were used to assess patient eligibility: 1) >18 years of age, 2) diagnosis of amblyopia, 3) diagnosis of cataract and treatment with surgery, 4) electronic medical record contains pre-surgery and post-surgery visual acuity (VA) measurements, 5) electronic medical record contains information on whether the patient was ever prescribed a SSRI/SNRI and the treatment duration, and 6) interocular VA difference of two lines or more on Snellen chart prior to cataract surgery. From each record, preoperative VA, postoperative VA, date of surgery, date at which postoperative VA was measured, and age at surgery were collected.
A total of 237 patients were included, with 38 of them being on SSRI/SNRI. The mean improvement in VA after surgery was not significantly greater in patients on SSRI/SNRI (SSRI/SNRI: -0.276 logMAR, control: -0.192 logMAR, =0.15). Multivariable regression was subsequently performed and while holding all other variables constant, demonstrated a statistically significant improvement in VA in patients on SSRI/SNRI (95% CI: -0.194, -0.0116, =0.03). The regression analysis further demonstrated that advanced age has an adverse effect on the change in post-op VA (CI: 3.34×10 logMAR, 9.77×10 logMAR, <0.005). Worse baseline VA is associated with a greater improvement in post-op VA (95% CI: -0.659 logMAR, -0.463 logMAR, <0.005) but adverse effect on the absolute post-op VA (95% CI: 0.341 logMAR, 0.544 logMAR, <0.005).
This study suggests that patients with amblyopia undergoing cataract surgery may potentially have a greater visual improvement when treated with SSRI/SNRIs.
评估选择性5-羟色胺再摄取抑制剂(SSRI)/5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)药物联合白内障手术治疗成年弱视患者的效果。
对在约翰霍普金斯医院威尔默眼科研究所接受白内障手术的患者进行回顾性病历审查研究。采用六项纳入标准评估患者是否符合条件:1)年龄>18岁;2)弱视诊断;3)白内障诊断及手术治疗;4)电子病历包含术前和术后视力(VA)测量值;5)电子病历包含患者是否曾服用SSRI/SNRI及治疗持续时间的信息;6)白内障手术前斯内伦视力表上两眼视力差异两行或更多。从每份病历中收集术前视力、术后视力、手术日期、测量术后视力的日期以及手术时的年龄。
共纳入237例患者,其中38例服用SSRI/SNRI。服用SSRI/SNRI的患者术后视力的平均改善并不显著更大(SSRI/SNRI:-0.276对数最小分辨角,对照组:-0.192对数最小分辨角,P = 0.15)。随后进行多变量回归,在保持所有其他变量不变的情况下,服用SSRI/SNRI的患者视力有统计学显著改善(95%置信区间:-0.194,-0.0116,P = 0.03)。回归分析进一步表明,高龄对术后视力变化有不利影响(置信区间:3.34×10对数最小分辨角,9.77×10对数最小分辨角,P<0.005)。较差的基线视力与术后视力更大的改善相关(95%置信区间:-0.659对数最小分辨角,-0.463对数最小分辨角,P<0.005),但对术后绝对视力有不利影响(95%置信区间:0.341对数最小分辨角,0.544对数最小分辨角,P<0.005)。
本研究表明,接受白内障手术的弱视患者在接受SSRI/SNRI治疗时可能有更大的视力改善。